I am not an expert in all this. I do not know your credentials either. However, the UCLA studies apparently did involve molecular sub groups and made some conclusions therefrom. Dr. LL is a principal investigator in the US for this phase III trial and who was also involved in the prior UCLA studies. Drs. LL and RP made some important findings wrt MES, pro neural and classical. LP according to my recollection referenced molecular sub groups as possible multiple chances to win. In speaking with LG, he confirmed that sub group analysis would be part of the study. Even Dr. Boynton indicated that we would know something when the trial was unblinded and data analysis was completed. So you will forgive me if I withhold judgement on your rather dogmatic statement.
Accordingly, I find it difficult to believe that molecular sub group data was not collected for analysis and that nothing deeper than methylation status was collected as a rather limited basis for data collection and analysis.
In any event, we will find out who is right after the trial is unblinded and the full results are revealed.
Stay tuned.
News 
Market Data 
Discover 
AI
